NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs

Figure 3

Immunohistochemical expression in patient samples. (a-d) NRF1 C-terminal antibody, benign naevus, dysplastic naevus, primary melanoma, and metastatic melanoma from a lymph node, respectively, diaminobenzidine and haematoxylin, (e-h) NRF1 N-terminal antibody, benign naevus, dysplastic naevus, primary melanoma, and metastatic melanoma from a lymph node, respectively, Fast Red and haematoxylin, and (i-l) p40-NRF2, benign naevus, dysplastic naevus, primary melanoma, and metastatic melanoma from a lymph node, respectively, diaminobenzidine and haematoxylin.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)